Device Trial Radar · NCT06144827
A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer
Last checked: Nov 20, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 2025
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- Montefiore Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- HepQuant, LLC; Perspectum
- First posted
- Nov 22, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the role of quantitative MR imaging and blood-based biomarkers to measure liver function in patients receiving radiation therapy for liver cancer or cancer that has spread to the liver.
Conditions
- Cancer, Hepatocellular
- Radiotherapy Side Effect
Interventions
Multiparametric MRI scansDevice
Multiparametric MRI scans will be used to evaluate baseline degree of liver fibroinflammation and function as well as temporal changes in liver fibroinflammation and function using MRI-based LiverMultiScan software. We will also measure liver function using HepQuant SHUNT test in a subset of patients enrolled in this study.
Multiparametric MRI scans + HepQuantShunt TestDevice
Eligible patients can have previously undergone any modality and number of prior treatments for their hepatic malignancies, must be considered for either liver photon or proton radiation in the de-novo or re-irradiation setting and can be simultaneously enrolled on parallel trials. Patients must not have any contraindications that would preclude MRI imaging or receipt of HepQuant SHUNT test for those agreeable to have HepQuant SHUNT test.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility of Quantitative Multiparametric MRITime frame: Up to 12 Months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.